Related Experiment Videos
Tissue-specific transformation by oncogenic mutants of epidermal growth factor receptor
1William K. Warren Medical Research Institute, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City 73190, USA.
Abstract:
Mutations in the receptor for the epidermal growth factor provide valuable insight into mechanisms of growth control. Oncogenic mutants of this receptor tyrosine kinase cause erythroid leukemia, fibrosarcoma, angiosarcoma, glioblastoma, and melanoma. Mutations in the avian protooncogene occur by retroviral mechanisms. Deletion of the ligand-binding domain results in erythroblastosis, while additional mutations in cytoplasmic structures broaden the disease potential to other cell types. A carboxyl-terminal structure of erbB oncogenes modulates growth responses in a complex, cell-specific manner; this tissue-specificity region appears to promote growth in erythroblasts and to produce trans-dominant inhibition in fibroblasts. Human glioblastoma multiforme frequently contains receptor mutations that are reminiscent of avian oncogenes. In hereditary melanoma of Xiphophorus, aberrant regulation of transcription by a recombinant promoter determines tissue-specific tumorigenesis. The diversity of oncogenic mutations raises important questions concerning the roles of several receptor structures. The extracellular domain inhibits the receptor when unoccupied by ligand, for example, through a mechanism that is unknown. The auto-phosphorylation sites are dispensable for transformation, so their function in neoplastic growth is unclear. The carboxyl-terminal region promotes or blocks transformation in different tissues, suggesting complex regulation by unknown cellular factors. These issues are critical to understanding of the mechanisms of receptor activation and tissue tropism for this family of oncogenes.
Insights
Mutations in the epidermal growth factor receptor (EGFR) and related oncogenes drive various cancers. Understanding how EGFR mutations affect cell growth and tissue specificity is key to cancer research.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase are implicated in various cancers, including leukemia, fibrosarcoma, and glioblastoma.
- Avian protooncogenes provide models for studying EGFR mutations, with deletions in the ligand-binding domain causing erythroblastosis and cytoplasmic mutations broadening disease potential.
- The carboxyl-terminal region of erbB oncogenes exhibits cell-specific modulation of growth responses, promoting erythroblast growth and inhibiting fibroblast growth.
Purpose of the Study:
- To investigate the mechanisms of growth control related to mutations in the epidermal growth factor receptor (EGFR).
- To explore the diverse roles of different receptor structures in oncogenesis and tissue-specific tumorigenesis.
- To clarify the function of extracellular domains, auto-phosphorylation sites, and carboxyl-terminal regions in receptor activation and neoplastic growth.
Main Methods:
- Analysis of oncogenic mutants of receptor tyrosine kinases, including avian protooncogenes.
- Examination of mutations in human glioblastoma multiforme and hereditary melanoma.
- Investigating the effects of deletions in the ligand-binding domain and mutations in cytoplasmic structures.
Main Results:
- Oncogenic EGFR mutants are linked to erythroid leukemia, fibrosarcoma, angiosarcoma, glioblastoma, and melanoma.
- Deletion of the ligand-binding domain leads to erythroblastosis; additional mutations expand disease potential.
- The carboxyl-terminal region's role in transformation is tissue-specific, promoting growth in some cells and inhibiting it in others.
Conclusions:
- The diversity of oncogenic mutations highlights the complex roles of EGFR structures in cancer development.
- The extracellular domain's inhibitory function when unoccupied by ligand requires further investigation.
- Understanding receptor activation mechanisms and tissue tropism is critical for targeting this family of oncogenes in cancer therapy.